United States · FDA National Drug Code directory
Imlygic
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 55513-079_4d1843a8-7a83-4062-ba8c-4f97e2f1427b
- Product NDC
- 55513-079
- Form
- INJECTION, SUSPENSION
- Composition / generic term
- talimogene laherparepvec
- Labeler
- Amgen Inc
- Marketing category
- BLA
- Marketing start / end (source format)
- 20151102
- Source listing expiry
- 20261231
Source-listed ingredients
- TALIMOGENE LAHERPAREPVEC — 100000000 [PFU]/mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL in 1 CARTON (55513-079-01) / 1 mL in 1 VIAL · 55513-079-01
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →